STAA Quote, Financials, Valuation and Earnings

OrthoPediatrics has a net margin of -69.92% compared to Staar Surgical's net margin of -30.51%. Staar Surgical's return on equity of -5.02% beat OrthoPediatrics's return on equity of -10.25%.

Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 4.93%. On the other hand OrthoPediatrics has an analysts' consensus of $39.00 which suggests that it could grow by 57.64%. Given that OrthoPediatrics has higher upside potential than Staar Surgical, analysts believe OrthoPediatrics is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.767%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $49M, which are smaller than OrthoPediatrics quarterly revenues of $52.7M. Staar Surgical's net income of -$34.2M is lower than OrthoPediatrics's net income of -$16.1M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.80x versus 2.79x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -69.92% compared to Staar Surgical's net margin of -307.83%. Staar Surgical's return on equity of -5.02% beat Innovative Eyewear's return on equity of -105.44%.

Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 4.93%. On the other hand Innovative Eyewear has an analysts' consensus of $9.00 which suggests that it could grow by 228.56%. Given that Innovative Eyewear has higher upside potential than Staar Surgical, analysts believe Innovative Eyewear is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $49M, which are larger than Innovative Eyewear quarterly revenues of $690.7K. Staar Surgical's net income of -$34.2M is lower than Innovative Eyewear's net income of -$2.1M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.80x versus 2.46x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of -69.92% compared to Staar Surgical's net margin of -27.95%. Staar Surgical's return on equity of -5.02% beat NexGel's return on equity of -63.18%.

Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 4.93%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 108.33%. Given that NexGel has higher upside potential than Staar Surgical, analysts believe NexGel is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $49M, which are larger than NexGel quarterly revenues of $3M. Staar Surgical's net income of -$34.2M is lower than NexGel's net income of -$850K. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.80x versus 2.16x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

Pro-Dex has a net margin of -69.92% compared to Staar Surgical's net margin of 12.15%. Staar Surgical's return on equity of -5.02% beat Pro-Dex's return on equity of 21.59%.

Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 4.93%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could grow by 11.96%. Given that Pro-Dex has higher upside potential than Staar Surgical, analysts believe Pro-Dex is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison Pro-Dex has a beta of 0.682, suggesting its less volatile than the S&P 500 by 31.755%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $49M, which are larger than Pro-Dex quarterly revenues of $16.8M. Staar Surgical's net income of -$34.2M is lower than Pro-Dex's net income of $2M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while Pro-Dex's PE ratio is 24.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.80x versus 2.69x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.